Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InCode BioPharmaceutics, a company engaged in complement depletion, has appointed Kevin Stark as its new president and CEO.
Subscribe to our email newsletter
Most recently, Dr Stark served as an executive director at Amgen, and COO at iZumi Bio. Dr Stark latest responsibilities include strategic operations within R&D, integration of mergers and acquisitions, licensing, and business development.
Dr Stark has received a PhD in pharmacology from the University of Washington, and a BS in zoology from Colorado State University.
InCode has also announced that William John has resigned as president and CEO, and will remain on the board of directors. In conjunction with this transition, the company will shift operations from the San Francisco, California location to the Thousand Oaks, California area.
Jay Lichter, chairman of the board at InCode, said: “We are very pleased to appoint Kevin Stark as our CEO. We believe his experience, which spans basic research to executive management, will be instrumental as the company advances into drug development and seeks potential partnerships.”